2-氨基-5-溴-4-氯苯甲酸甲酯 | 765211-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-溴-4-氯苯甲酸甲酯
• 英文名称: methyl 2-amino-5-bromo-4-chlorobenzoate
• CAS: 765211-09-4
• 化学式: C₈H₇BrClNO₂
• 分子量: 264.506
• InChiKey: ZPXIVPLXMVFFKP-UHFFFAOYSA-N

物化性质

• 沸点：
  323.8±37.0 °C(Predicted)
• 密度：
  1.676±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  应存放在室温、避光、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 2-amino-5-bromo-4-chlorobenzoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 2-amino-5-bromo-4-chlorobenzoate
CAS number: 765211-09-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7BrClNO2
Molecular weight: 264.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-5-溴-4-氯苯甲酸甲酯 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以98%的产率得到(2-amino-5-bromo-4-chlorophenyl)methanol
  参考文献：
  名称：

  PARASITICIDAL COMPOSITIONS COMPRISING INDOLE DERIVATIVES, METHODS AND USES THEREOF

  摘要：

  该发明涉及用于对抗哺乳动物体内肝吸虫寄生虫的口服、局部或注射组合物，包括至少一种吲哚衍生物活性剂。该发明还提供了一种改进的方法，用于根除和控制哺乳动物体内肝吸虫寄生虫感染和寄生，包括向需要的哺乳动物体内给予本发明的组合物。

  公开号：

  US20150366198A1
• 作为产物：
  描述：

  甲基2-胺-4-氯苯酚酯 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-氨基-5-溴-4-氯苯甲酸甲酯
  参考文献：
  名称：

  偏头痛，口服生物利用度和中枢神经系统渗透性神经降压素受体1（NTR1）变构调节剂的β-抑制蛋白的发现。

  摘要：

  神经降压素受体1（NTR1）是一种G蛋白偶联受体，在整个中枢神经系统中广泛表达，在其中它充当神经调节剂。神经降压素受体与多种中枢神经系统疾病有关，但是尽管为开发小分子配体付出了巨大的努力，但很少有此类化合物的报道。在这里，我们描述了基于喹唑啉的铅的优化，以得到18（SBI-553），这是一种有效的脑渗透NTR1变构调节剂。

  DOI：

  10.1021/acs.jmedchem.9b00340

文献信息

• [EN] COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA<br/>[FR] COMPOSES ET TECHNIQUES DE TRAITEMENT DE LA DYSLIPIDEMIE
  申请人：LILLY CO ELI

  公开号：WO2005037796A1

  公开（公告）日：2005-04-28

  Compounds of formula I wherein n, m, p, q, Y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

  式I的化合物，其中n、m、p、q、Y、R1、R2、R3、R4、R5和R6如本文所定义，并且其药物组合物和使用方法被披露为用于治疗动脉粥样硬化及其后遗症。
• [EN] INHIBITORS OF KRAS G12C<br/>[FR] INHIBITEURS DE K-RAS G12C
  申请人：ARAXES PHARMA LLC

  公开号：WO2015054572A1

  公开（公告）日：2015-04-16

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。这些化合物具有以下结构（I）：或其药用可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E如本文所定义。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的药物组合物以及调节G12C突变KRAS蛋白活性以治疗癌症等疾病的方法。
• [EN] COMBINATION THERAPIES FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIES COMBINATOIRES POUR LE TRAITEMENT DU CANCER
  申请人：ARAXES PHARMA LLC

  公开号：WO2016044772A1

  公开（公告）日：2016-03-24

  Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

  提供用于治疗与KRAS基因突变相关的癌症的联合疗法。还提供了包含治疗剂的组合物，用于治疗与KRAS基因突变相关的癌症。
• Optimization and Evaluation of Antiparasitic Benzamidobenzoic Acids as Inhibitors of Kinetoplastid Hexokinase 1
  作者：Daniel P. Flaherty、Michael T. Harris、Chad E. Schroeder、Haaris Khan、Elizabeth W. Kahney、Amber L. Hackler、Stephen L. Patrick、Warren S. Weiner、Jeffrey Aubé、Elizabeth R. Sharlow、James C. Morris、Jennifer E. Golden

  DOI：10.1002/cmdc.201700592

  日期：2017.12.7

  molecular‐target‐directed approach involving intervention of hexokinase activity—a pivotal enzyme in parasite metabolism. A benzamidobenzoic acid hit with modest biochemical inhibition of Trypanosoma brucei hexokinase 1 (TbHK1, IC50=9.1 μm), low mammalian cytotoxicity (IMR90 cells, EC50>25 μm), and no appreciable activity on whole bloodstream‐form (BSF) parasites was optimized to afford a probe with improved TbHK1 potency

  基于动质体的感染是被忽视的疾病，代表着重大的人类健康问题。由于毒性、寄生虫敏感性和患者依从性差，化疗选择受到限制。为此，我们研究了一种分子靶点导向的方法，涉及干预己糖激酶活性（寄生虫代谢中的关键酶）。苯甲酰胺苯甲酸对布氏锥虫己糖激酶 1 (TbHK1，IC 50 =9.1 μm )具有适度的生化抑制作用，对哺乳动物细胞毒性低（IMR90 细胞，EC 50 >25 μm ），并且对全血流形式 (BSF) 无明显活性）寄生虫经过优化，以提供具有改进的 TbHK1 效力的探针，并且显着地提高了针对整个 BSF 寄生虫的效力（TbHK1，IC 50 = 0.28 μ m；BSF，ED 50 = 1.9 μ m）。该系列化合物还抑制了来自大型利什曼原虫(LmHK1)的己糖激酶，尽管其效力低于 TbHK1，这表明糖酵解途径的抑制可能是针对多种致病锥虫原生动物的一个有希望的机会。
• Enzymatic and Structural Characterization of the <i>Naegleria fowleri</i> Glucokinase
  作者：Jillian E. Milanes、Jimmy Suryadi、Jan Abendroth、Wesley C. Van Voorhis、Kayleigh F. Barrett、David M. Dranow、Isabelle Q. Phan、Stephen L. Patrick、Soren D. Rozema、Muhammad M. Khalifa、Jennifer E. Golden、James C. Morris

  DOI：10.1128/aac.02410-18

  日期：2019.5

  apparent Km values of 42.5 ± 7.3 μM and 141.6 ± 9.9 μM for glucose and ATP, respectively. The NfGlck structure was determined and refined to 2.2-Å resolution, revealing that the enzyme shares greatest structural similarity with the Trypanosoma cruzi Glck. These similarities include binding modes and binding environments for substrates. To identify inhibitors of NfGlck, we screened a small collection of inhibitors

  自由生活的变形虫纳氏菌感染会导致威胁生命的原发性阿米巴脑膜脑炎。这些感染的有效治疗选择有限，并且死亡率非常高（〜98％）。寄生虫代谢可能为治疗设计提供合适的靶标。像大多数其他生物一样，葡萄糖代谢对于寄生虫的生存能力至关重要，这是培养物中生长所必需的。葡萄糖代谢所需的第一个酶通常是己糖激酶（HK），它可以将磷酸从ATP转移到葡萄糖。该酶的产物对于糖酵解和磷酸戊糖途径都是必需的。但是，福勒猪笼草的基因组缺乏明显的HK同源物，而是带有一个葡萄糖激酶（Glck）。然后。Fowleri Glck（NfGlck）与哺乳动物宿主酶（Homo sapiens Glck）共享有限的（25％）氨基酸同一性，这表明可以生成具有抗阿米巴活性的寄生虫特异性抑制剂。在异源表达之后，发现NfGlck具有有限的己糖底物范围，用葡萄糖观察到最大的活性。该酶的葡萄糖和ATP的表观Km值分别为42.5±7.3μM和141.6±9